STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024
Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024
26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, will present late breaking data on STORM’s METTL1 inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held 5-10 April 2024.
